- $705.44m
- $672.81m
- $455.07m
- 95
- 87
- 97
- 100
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 84.5 | 67.2 | 199 | 354 | 455 |
Cost of Revenue | |||||
Gross Profit | 54.7 | 37.8 | 131 | 254 | 305 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 63.3 | 94.4 | 120 | 183 | 296 |
Operating Profit | 21.2 | -27.3 | 79.1 | 171 | 159 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 21 | -20.4 | 59.8 | 123 | 150 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.85 | -48.1 | 81.9 | 52 | 60.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 2.52 | -48.2 | 81.8 | 51.9 | 60.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 2.54 | -48.2 | 81.8 | 51.9 | 59.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.048 | -0.489 | 1.39 | 0.796 | 0.589 |
Dividends per Share |